Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera

Fig. 1

A Bar graph showing the complete hematologic response (CHR) rates at 12 and 24 weeks. B Kaplan–Meier plot showing time to CHR. C Graph showing mean JAK2V617F allele burden change. Diamond indicates the mean value. D Waterfall plot showing the change of the JAK2V617F allele burden in individual patients. Patients who had a CHR are indicated in blue

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us